ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for charts Register for streaming realtime charts, analysis tools, and prices.

SMMT Summit Therapeutics Inc

4.65
0.72 (18.32%)
02 May 2024 - Closed
Delayed by 15 minutes
Name Symbol Market Type
Summit Therapeutics Inc NASDAQ:SMMT NASDAQ Depository Receipt
  Price Change % Change Price Bid Price Offer Price High Price Low Price Open Price Traded Last Trade
  0.72 18.32% 4.65 4.64 4.74 4.99 3.90 3.92 5,653,111 00:00:02

Summit Therapeutics to Present at the 2019 BIO Investor Forum

16/10/2019 12:00pm

GlobeNewswire Inc.


Summit Therapeutics (NASDAQ:SMMT)
Historical Stock Chart


From May 2019 to May 2024

Click Here for more Summit Therapeutics Charts.

Summit Therapeutics plc  (‘Summit’ or the ‘Company’)

Summit Therapeutics to Present at the 2019 BIO Investor Forum

Oxford, UK, and Cambridge, MA, US, 16 October 2019 – Summit Therapeutics plc (NASDAQ: SMMT, AIM: SUMM) announces that Mr Glyn Edwards, Chief Executive Officer, will present at the 2019 BIO Investor Forum on 22 October 2019 at 10:45am PDT in San Francisco.

A live webcast of the presentation will be available in the Investors section of the Company's website, www.summitplc.com. A replay of the webcast will be available from the same location soon after the live presentation.

About Summit Therapeutics Summit Therapeutics is a leader in antibiotic innovation. Our new mechanism antibiotics are designed to become the new standards of care for the benefit of patients and create value for payors and healthcare providers. We are currently developing new mechanism antibiotics for infections caused by C. difficile, N. gonorrhoeae and Enterobacteriaceae and are using our proprietary Discuva Platform to expand our pipeline. For more information, visit www.summitplc.com and follow us on Twitter @summitplc.

Contacts

Summit    
Glyn Edwards / Richard Pye (UK office) Tel: 44 (0)1235 443 951
Michelle Avery (US office)   +1 617 225 4455
     
Cairn Financial Advisers LLP (Nominated Adviser) Tel: +44 (0)20 7213 0880
Liam Murray / Tony Rawlinson    
     
N+1 Singer (Joint Broker) Tel: +44 (0)20 7496 3000
Aubrey Powell / Jen Boorer, Corporate FinanceTom Salvesen, Corporate Broking    
     
Bryan Garnier & Co Limited (Joint Broker) Tel: +44 (0)20 7332 2500
Phil Walker / Dominic Wilson      
MSL Group (US) Tel: +1 781 684 6652
Erin Anthoine   summit@mslgroup.com
     
Consilium Strategic Communications (UK) Tel: +44 (0)20 3709 5700
Mary-Jane Elliott / Sue Stuart / Sukaina Virji   summit@consilium-comms.com
Lindsey Neville    

-END-

1 Year Summit Therapeutics Chart

1 Year Summit Therapeutics Chart

1 Month Summit Therapeutics Chart

1 Month Summit Therapeutics Chart

Your Recent History

Delayed Upgrade Clock